rewirebio.iobenchmarks
Source

CIViC MCP supplementary methods and complete Tables 1–3

vbag209_supplementary_data.docx, final article supplement · Peer-reviewed

DOI: 10.1093/bioadv/vbag209Original source

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationAccuracy0.83 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: diagnostic negative)0.00 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: diagnostic positive)0.94 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: functional dominant negative)1.00 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: functional gain of function)0.67 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: functional loss of function)0.92 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: functional unaltered function)1.00 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: oncogenic oncogenicity)0.96 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predictive reduced sensitivity)1.00 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predictive resistance)0.94 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predictive sensitivity)0.88 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predisposing n/a)0.88 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predisposing predisposition)0.96 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: predisposing uncertain significance)0.92 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: prognostic better outcome)1.00 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationF1 (class: prognostic poor outcome)0.89 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F10.91 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: diagnostic)0.84 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: functional)0.88 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: oncogenic)0.96 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: predictive)0.90 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: predisposing)0.93 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationMicro F1 (evidence type: prognostic)0.95 unitlessCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: diagnostic negative)0.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: diagnostic positive)0.89 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: functional dominant negative)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: functional gain of function)0.75 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: functional loss of function)0.86 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: functional unaltered function)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: oncogenic oncogenicity)0.92 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predictive reduced sensitivity)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predictive resistance)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predictive sensitivity)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predisposing n/a)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predisposing predisposition)0.93 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: predisposing uncertain significance)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: prognostic better outcome)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationPrecision (class: prognostic poor outcome)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: diagnostic negative)0.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: diagnostic positive)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: functional dominant negative)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: functional gain of function)0.60 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: functional loss of function)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: functional unaltered function)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: oncogenic oncogenicity)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: predictive reduced sensitivity)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: predictive resistance)0.88 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: predictive sensitivity)0.79 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: predisposing n/a)0.78 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval
ChatGPT Agent Mode, 2–7 March 2026 CIViC evaluationRecall (class: predisposing predisposition)1.00 fractionCIViC 100 molecular-profile/disease/therapy triplets, March 2026CIViC agent retrieval

Claims

Statements this source supports, each with where in the source it was checked.

Models, benchmarks and other records

Configurations (4)

Pipelines (1)

Benchmarks (1)

Protocols (1)

Datasets (1)

Baselines (3)

Evaluations (3)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

17 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive doi
10.5281/zenodo.20938836
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_doi

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact retrieved at
2026-09-30T21:25:48Z
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_retrieved_at

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://academic.oup.com/bioinformaticsadvances/article/6/1/vbag209/8746878#supplementary-data
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1093/bioadv/vbag209
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-09-30T21:43:37Z
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Url
https://academic.oup.com/bioinformaticsadvances/article/6/1/vbag209/8746878#supplementary-data
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.url

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Version
vbag209_supplementary_data.docx, final article supplement
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.version

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Description
Primary source inspected for the scoped extraction; automated review does not establish replication.
Source metadata
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

No field-specific location recorded

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

catalogued

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source inspected for the scoped extraction; automated review does not establish replication.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: uc-clinical-20260930-source-civic-supp

areas
dna-genomes
contexts
clinical_research
url
https://academic.oup.com/bioinformaticsadvances/article/6/1/vbag209/8746878#supplementary-data
retrieved at
2026-09-30T21:43:37Z
version
vbag209_supplementary_data.docx, final article supplement
publication status
peer_reviewed
archive doi
10.5281/zenodo.20938836
doi
10.1093/bioadv/vbag209
artifact sha256
857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6
artifact url
https://academic.oup.com/bioinformaticsadvances/article/6/1/vbag209/8746878#supplementary-data
artifact retrieved at
2026-09-30T21:25:48Z
Related records

    Suggest a correction